There is a dire need for a simpler and more affordable device and method that allows for a simplified but accurate imaging of a person’s retina to detect symptoms of diabetic retinopathy especially at the periphery of the retina:
• Detected early and treated effectively, retinopathy can be halted so that vision can be maintained.
• Early diagnosis is a critical factor in broadening care and prevention.
The RetinalGeniX system is designed to provide the next generation of cost-effective, ultra-wide-imaging technologies to examine the periphery of the Retina at up to an unparalleled 200 degree field of view, in order to detect early signs of Diabetic Retinopathy without having to dilate the patient's pupil.
Ophthalmologists, Retina Specialists and Optometrists diagnosing diabetic retinopathy are the target market for the RetinalGenix system:
• Globally, there are 206,000 Ophthalmologists within these markets:
o US and Canada - 26,000
o European Union - 34,466
o Russian Federation - 14,600
o Asia, excluding Japan and China - 10,055
o China - 28,338
o Japan - 13,991
o Central and South American markets are as follows:
1. Brazil - 11,350
2. Colombia - 1,250
3. Mexico - 3,500
4. Peru - 1,050
5. Venezuela - 3,000
o India - 11,000
o Other notable markets include:
1. Turkey - 3,080
o Ukraine - 3,550
• In addition, globally, there are over 200,000 Optometrists, in roughly the same geographic proportions as Ophthalmologists.
The RetinalGeniX system has a distinct competitive advantage because it not only combines the very best features of currently marketed technologies but also has two extremely critical additional features: (1) portability, which allows the system too be used in a clinical setting as well as in the field; and (2) a price point well below the average selling price (ASP) of current currently marketed systems, which is more than $25,000 per system.